Kong Qingliang, Kitaoka Momoko, Wakabayashi Rie, Tahara Yoshiro, Kamiya Noriho, Goto Masahiro
Department of Applied Chemistry, Graduate School of Engineering, Kyushu University, Fukuoka 819-0395, Japan.
Advanced Transdermal Drug Delivery System Center, Kyushu University, Fukuoka 819-0395, Japan.
Pharmaceutics. 2020 Mar 7;12(3):240. doi: 10.3390/pharmaceutics12030240.
Japanese cedar pollinosis (JCP) is a common affliction caused by an allergic reaction to cedar pollen and is considered a disease of national importance in Japan. Antigen-specific immunotherapy (AIT) is the only available curative treatment for JCP. However, low compliance and persistence have been reported among patients subcutaneously or sublingually administered AIT comprising a conventional antigen derived from a pollen extract. To address these issues, many research studies have focused on developing a safer, simpler, and more effective AIT for JCP. Here, we review the novel antigens that have been developed for JCP AIT, discuss their different administration routes, and present the effects of anti-allergy treatment. Then, we describe a new form of AIT called transcutaneous immunotherapy (TCIT) and its solid-in-oil (S/O) nanodispersion formulation, which is a promising antigen delivery system. Finally, we discuss the applications of S/O nanodispersions for JCP TCIT. In this context, we predict that TCIT delivery by using a S/O nanodispersion loaded with novel antigens may offer an easier, safer, and more effective treatment option for JCP patients.
日本雪松花粉症(JCP)是一种由对雪松花粉的过敏反应引起的常见疾病,在日本被视为具有国家重要性的疾病。抗原特异性免疫疗法(AIT)是JCP唯一可用的治愈性治疗方法。然而,据报道,皮下或舌下给予包含源自花粉提取物的传统抗原的AIT的患者中,依从性和持续性较低。为了解决这些问题,许多研究致力于为JCP开发更安全、更简单且更有效的AIT。在此,我们综述了已为JCP AIT开发的新型抗原,讨论了它们不同的给药途径,并介绍了抗过敏治疗的效果。然后,我们描述了一种称为经皮免疫疗法(TCIT)的新型AIT形式及其油包固(S/O)纳米分散体制剂,这是一种有前景的抗原递送系统。最后,我们讨论了S/O纳米分散体在JCP TCIT中的应用。在这种情况下,我们预测使用负载新型抗原的S/O纳米分散体进行TCIT递送可能为JCP患者提供一种更简便、更安全且更有效的治疗选择。